Decision Resources, Inc., announces the publication of Emerging Delivery Systems for Biopharmaceuticals, a new DR Report that offers crucial strategic analysis for companies developing biological products. When addressed too late in the developmental process, drug delivery can present an insurmountable hurdle to the successful development of a drug candidate. In this report, we review the various forms of drug delivery systems and the main indications for which they are being developed. We also evaluate the efforts of drug delivery companies working to improve formulations and delivery methods for biopharmaceuticals. The following drug delivery systems are discussed in detail:

  -- Micro- and nanoparticles.   -- Liposomes and emulsions.   -- Pegylation technology.   -- Buccal delivery.   -- Nasal delivery.   -- Pulmonary delivery.   -- Transdermal delivery.   -- Cell therapy.    (Photo: ) 

Major pharmaceutical companies are increasingly looking to drug delivery companies to develop new systems to ensure successful launches of the next generation of large-molecule drugs. Emerging Delivery Systems for Biopharmaceuticals provides biological drug companies with critical intelligence on delivery technologies crucial to the success of their products.

We believe that recent innovations in drug delivery technology will optimize the use of large-molecule drugs over the next decade. Drug delivery companies can anticipate a wealth of business opportunities as they work to accommodate and optimize the rapid developments of drugs based on proteins, peptides, and oligonucleotides. Our forecast indicates that by 2005, sales of proteins and peptides employing novel delivery systems will total at least $2.25 billion. By 2010, we expect sales to reach $10.1 billion.

Emerging Delivery Systems for Biopharmaceuticals is a publication of DR Reports, a service of Decision Resources.

Decision Resources, Inc., is a world leader in research publications and advisory services designed to help clients shape strategy, allocate resources, and master their chosen markets. Founded as a subsidiary of Arthur D. Little, Inc., the company has provided strategic information services for 30 years, assessing international pharmaceutical and health care industry trends. Visit Decision Resources at

Contact Fran Cameron, 781.296.2568 (tel), 781.296.2525 (fax), or In Europe, contact Francoise Bidart, +32.2.351.4082 (tel), +32.2.351.2347 (fax), or In Japan, contact Makiko Yoshimoto, +81.3.5401.2615 (tel), +81.3.5401.2617 (fax), or


AP Archive:

PRN Photo Desk, 888-776-6555 or 212-782-2840

SOURCE: Decision Resources, Inc.

Contact: Fran Cameron of Decision Resources, Inc., 781-296-2568,

Decision Resources Study Finds Emerging Chronic Leukemia Therapies Are Expected to Revolutionize Medical Practice and Fuel Huge Market Growth

View Now